Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.


Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.


Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.


Studies on Steroid Receptor Coactivators in Prostate Cancer.

Culig Z, Santer FR.

Methods Mol Biol. 2018;1786:259-262. doi: 10.1007/978-1-4939-7845-8_15.


Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.

Urbiola C, Santer FR, Petersson M, van der Pluijm G, Horninger W, Erlmann P, Wollmann G, Kimpel J, Culig Z, von Laer D.

Int J Cancer. 2018 Apr 26. doi: 10.1002/ijc.31556. [Epub ahead of print]


Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR.

Mol Oncol. 2018 Apr;12(4):561-576. doi: 10.1002/1878-0261.12185. Epub 2018 Mar 15.


Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Erb HHH, Guggenberger F, Santer FR, Culig Z.

J Cell Biochem. 2018 May;119(5):4103-4112. doi: 10.1002/jcb.26607. Epub 2018 Jan 19.


The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.


The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.

Luef B, Handle F, Kharaishvili G, Hager M, Rainer J, Janetschek G, Hruby S, Englberger C, Bouchal J, Santer FR, Culig Z.

Endocr Relat Cancer. 2016 Jun;23(6):495-508. doi: 10.1530/ERC-16-0160. Epub 2016 Jun 2.


SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Handle F, Erb HH, Luef B, Hoefer J, Dietrich D, Parson W, Kristiansen G, Santer FR, Culig Z.

Mol Cancer Res. 2016 Jun;14(6):574-85. doi: 10.1158/1541-7786.MCR-15-0495. Epub 2016 Apr 6.


DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J.

Mol Oncol. 2016 Jun;10(6):879-94. doi: 10.1016/j.molonc.2016.02.005. Epub 2016 Mar 3.


Therapy escape mechanisms in the malignant prostate.

Santer FR, Erb HH, McNeill RV.

Semin Cancer Biol. 2015 Dec;35:133-44. doi: 10.1016/j.semcancer.2015.08.005. Epub 2015 Aug 21. Review.


Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.

Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane JK, Maitland NJ, Klocker H, Eder IE, Culig Z.

Oncotarget. 2015 Mar 20;6(8):6105-22.


Androgen receptor signaling in prostate cancer.

Culig Z, Santer FR.

Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27. doi: 10.1007/s10555-013-9474-0. Review.


IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.

Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall B, Sasser K, Culig Z, Santer FR.

Endocr Relat Cancer. 2013 Aug 23;20(5):677-89. doi: 10.1530/ERC-13-0222. Print 2013 Oct.


Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.

Culig Z, Santer FR.

Steroids. 2013 Sep;78(9):851-9. doi: 10.1016/j.steroids.2013.04.012. Epub 2013 Apr 30.


Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z.

Endocr Relat Cancer. 2012 May 3;19(3):305-19. doi: 10.1530/ERC-11-0298. Print 2012 Jun.


Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

Culig Z, Santer FR.

World J Urol. 2012 Jun;30(3):297-302. doi: 10.1007/s00345-011-0797-6. Epub 2011 Nov 22. Review.


Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.

Santer FR, Höschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA, Culig Z.

Mol Cancer Ther. 2011 Sep;10(9):1644-55. doi: 10.1158/1535-7163.MCT-11-0182. Epub 2011 Jun 27.


Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.

Bouchal J, Santer FR, Höschele PP, Tomastikova E, Neuwirt H, Culig Z.

Prostate. 2011 Mar 1;71(4):431-7. doi: 10.1002/pros.21257. Epub 2010 Sep 21.


SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z.

Endocr Relat Cancer. 2010 May 18;17(2):525-38. doi: 10.1677/ERC-10-0007. Print 2010 Jun.


Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells.

Santer FR, Malinowska K, Culig Z, Cavarretta IT.

Endocr Relat Cancer. 2010 Feb 18;17(1):241-53. doi: 10.1677/ERC-09-0200. Print 2010 Mar.


Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z.

Cancer Res. 2009 Sep 15;69(18):7375-84. doi: 10.1158/0008-5472.CAN-09-0806. Epub 2009 Sep 8.


Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z.

Am J Pathol. 2009 May;174(5):1921-30. doi: 10.2353/ajpath.2009.080751. Epub 2009 Mar 26.


High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.

Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR, Widschwendter A, Even J, Jansen-Dürr P, Capesius C, Zwerschke W.

Clin Cancer Res. 2007 Dec 1;13(23):7067-72.


Identification of the FHL2 transcriptional coactivator as a new functional target of the E7 oncoprotein of human papillomavirus type 16.

Campo-Fernández B, Morandell D, Santer FR, Zwerschke W, Jansen-Dürr P.

J Virol. 2007 Jan;81(2):1027-32. Epub 2006 Nov 8.


Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.

Santer FR, Bacher N, Moser B, Morandell D, Ressler S, Firth SM, Spoden GA, Sergi C, Baxter RC, Jansen-Dürr P, Zwerschke W.

Cancer Res. 2006 Mar 15;66(6):3024-33.

Supplemental Content

Loading ...
Support Center